标题
Engineering ACE2 decoy receptors to combat viral escapability
作者
关键词
-
出版物
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-07-26
DOI
10.1016/j.tips.2022.06.011
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
- (2022) Wanwisa Dejnirattisai et al. CELL
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
- (2022) Lianghui Zhang et al. Nature Chemical Biology
- An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- (2022) Laura A. VanBlargan et al. NATURE MEDICINE
- Protein design via deep learning
- (2022) Wenze Ding et al. BRIEFINGS IN BIOINFORMATICS
- An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
- (2022) Nariko Ikemura et al. Science Translational Medicine
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
- (2021) Tianshu Xiao et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
- (2021) C. Garrett Rappazzo et al. SCIENCE
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
- (2021) Jingxin Qiao et al. SCIENCE
- An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
- (2021) Kui K. Chan et al. Science Advances
- Structure-based molecular modeling in SAR analysis and lead optimization
- (2021) Veronika Temml et al. Computational and Structural Biotechnology Journal
- ACE2‐based decoy receptors for SARS coronavirus 2
- (2021) Wenyang Jing et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection
- (2021) Ami Miller et al. Scientific Reports
- Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
- (2021) Huihui Mou et al. PLoS Pathogens
- Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
- (2021) Hilal Ahmad Parray et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Tackling COVID-19 with neutralizing monoclonal antibodies
- (2021) Davide Corti et al. CELL
- Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity
- (2021) Brandon Havranek et al. Journal of Chemical Information and Modeling
- Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
- (2021) Mathieu Ferrari et al. JOURNAL OF VIROLOGY
- Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
- (2021) Rachel Yamin et al. NATURE
- Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
- (2021) Nir Drayman et al. SCIENCE
- Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
- (2021) Allison J. Greaney et al. Science Translational Medicine
- Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
- (2021) Wen Su et al. mBio
- Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
- (2021) Yusuke Higuchi et al. Nature Communications
- Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
- (2021) Joshua J. Sims et al. PLoS Pathogens
- Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
- (2021) Zhaoyong Zhang et al. Cell Discovery
- Update on and Future Directions for Use of Anti–SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19
- (2021) César Boggiano et al. ANNALS OF INTERNAL MEDICINE
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
- (2021) Markus Hoffmann et al. CELL
- Regdanvimab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Machine-Learning-Guided Library Design Cycle for Directed Evolution of Enzymes: The Effects of Training Data Composition on Sequence Space Exploration
- (2021) Yutaka Saito et al. ACS Catalysis
- Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
- (2021) Tümay Capraz et al. eLife
- Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19
- (2021) Keiji Kuba et al. Frontiers in Immunology
- ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
- (2021) Naoki Iwanaga et al. iScience
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Major Histocompatibility Complex Binding, Eluted Ligands, and Immunogenicity: Benchmark Testing and Predictions
- (2020) Sinu Paul et al. Frontiers in Immunology
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
- (2020) Vanessa Monteil et al. CELL
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
- (2020) Michelle F. Richter et al. NATURE BIOTECHNOLOGY
- Phylogenetic tree building in the genomic age
- (2020) Paschalia Kapli et al. NATURE REVIEWS GENETICS
- Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
- (2020) Changhai Lei et al. Nature Communications
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- Coronavirus RNA proofreading: molecular basis and therapeutic targeting
- (2020) Fran Robson et al. MOLECULAR CELL
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
- (2020) Kui K. Chan et al. SCIENCE
- A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
- (2020) Jakob Kreye et al. CELL
- Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation
- (2020) Sergio Decherchi et al. CHEMICAL REVIEWS
- SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
- (2020) Yujun Li et al. JOURNAL OF VIROLOGY
- Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
- (2020) Stylianos Bournazos et al. NATURE
- Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
- (2020) Anum Glasgow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection
- (2020) Rohan Narayan et al. Frontiers in Cellular and Infection Microbiology
- Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
- (2020) Hilma J. van der Horst et al. Cancers
- Potential SARS-CoV-2 main protease inhibitors
- (2020) Riddhidev Banerjee et al. DRUG DISCOVERY TODAY
- Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
- (2020) Fatai S. Oladunni et al. Nature Communications
- An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
- (2019) Chang-Han Lee et al. Nature Communications
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Methods for the directed evolution of proteins
- (2015) Michael S. Packer et al. NATURE REVIEWS GENETICS
- Direct measurements of particle–surface interactions in aqueous solutions with total internal reflection microscopy
- (2014) Xiangjun Gong et al. CHEMICAL COMMUNICATIONS
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
- (2013) Manuel Haschke et al. CLINICAL PHARMACOKINETICS
- Emerging Therapies for Neovascular Age-Related Macular Degeneration
- (2013) Peter K. Kaiser OPHTHALMOLOGY
- A preclinical and clinical review of aflibercept for the management of cancer
- (2012) Andrew Gaya et al. CANCER TREATMENT REVIEWS
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
- (2011) Qing Zhu et al. JOURNAL OF INFECTIOUS DISEASES
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
- (2009) Chichi Huang CURRENT OPINION IN BIOTECHNOLOGY
- Targeted Drug-Aerosol Delivery in the Human Respiratory System
- (2008) C. Kleinstreuer et al. Annual Review of Biomedical Engineering
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started